Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment.
Following recovery from a 4-hr exposure to clinically achievable concentrations of the topoisomerase II inhibitors Adriamycin, teniposide, or amsacrine or the putative topoisomerase II inhibitor crisnatol, murine erythroleukemic cells remained viable for up to 48 hr, but did not proliferate. Cell cycle analysis after a 24-hr recovery revealed blocks in G2 (4N DNA) or greater than G2 (up to 8N DNA) polyploid stages. The relative percentages of cells in either stage was a function of drug concentration and cell cycle stage at time of exposure: typically, cells exposed during S phase became blocked in G2, whereas those exposed during G2/M progressed into greater than G2 polyploid stages. G2-blocked cells exhibited a 2- to 3-fold increase in nuclear protein content and cellular/nuclear volume (i.e. unbalanced growth) and approximately 5% more DNA stainability (as a consequence of nuclear conformational changes rather than redundant DNA synthesis). In all cases, at the drug concentrations studied, mitotic figures were absent and G2 and greater than G2 blocks were irreversible, indicating that the mechanism of polyploidy induction differs from that of microtubule inhibitors. These findings suggest that although topoisomerase inhibitors interfere with DNA synthesis in the S phase, their induction of greater than G2 polyploid blocks may involve direct or indirect inhibition of chromosome condensation.
Zucker
R M
RM
ManTech Environmental Technology, Inc., Research Triangle Park, NC 27709.
Adams
D J
DJ
Bair
K W
KW
Elstein
K H
KH
D000677:Amsacrine / Q000494:pharmacology; D000818:Animals; D002166:Camptothecin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D005434:Flow Cytometry; D005622:Friend murine leukemia virus; D016195:G2 Phase / Q000187:drug effects / Q000502:physiology; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy / Q000235:genetics*; D051379:Mice; D011123:Polyploidy; D013713:Teniposide / Q000494:pharmacology; D013936:Thymidine / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D004317:Doxorubicin; D013713:Teniposide; D013936:Thymidine; D002166:Camptothecin